Literature DB >> 21111245

Examining the metastatic niche: targeting the microenvironment.

Theresa Guise1.   

Abstract

Some of the most common cancer types, including breast cancer, prostate cancer, and lung cancer, show a predilection to metastasize to bone. The molecular basis of this preferential growth of cancer cells in the bone microenvironment has been an area of active investigation. Although the precise molecular mechanisms underlying this process remain to be elucidated, it is now increasingly being recognized that the unique characteristics of the bone niche provide homing signals to cancer cells, and create a microenvironment conducive for the cancer cells to colonize. Concomitantly, cancer cells release several regulatory factors that result in abnormal bone destruction and/or formation. This complex bidirectional interplay between tumor cells and bone microenvironment establishes a "vicious cycle" that leads to a selective growth advantage for the cancer cells. The molecular insights gained on the underpinnings of bone metastasis in recent years have also provided us with avenues to devise innovative approaches for therapeutic intervention. The goal of this review is to describe our current understanding of molecular pathophysiology of cancer metastases to bone, as well as its therapeutic implications.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21111245     DOI: 10.1053/j.seminoncol.2010.10.007

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  50 in total

1.  Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Authors:  Bhavani Krishnan; Thomas L Smith; Purnima Dubey; Michael E Zapadka; Frank M Torti; Mark C Willingham; E Ann Tallant; Patricia E Gallagher
Journal:  Prostate       Date:  2012-05-29       Impact factor: 4.104

2.  Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.

Authors:  M Tandon; Z Chen; A H Othman; J Pratap
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

Review 3.  The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs.

Authors:  Robert R Langley; Isaiah J Fidler
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

4.  Converting cancer therapies into cures: lessons from infectious diseases.

Authors:  Michael S Glickman; Charles L Sawyers
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

5.  Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer.

Authors:  Jessalyn M Ubellacker; Ninib Baryawno; Nicolas Severe; Molly J DeCristo; Jaclyn Sceneay; John N Hutchinson; Marie-Therese Haider; Catherine S Rhee; Yuanbo Qin; Walter M Gregory; Ana C Garrido-Castro; Ingunn Holen; Janet E Brown; Robert E Coleman; David T Scadden; Sandra S McAllister
Journal:  Cancer Res       Date:  2018-07-31       Impact factor: 12.701

Review 6.  Metastatic stem cells: sources, niches, and vital pathways.

Authors:  Thordur Oskarsson; Eduard Batlle; Joan Massagué
Journal:  Cell Stem Cell       Date:  2014-03-06       Impact factor: 24.633

Review 7.  Cancer-induced oxidative stress and pain.

Authors:  Mina G Nashed; Matthew D Balenko; Gurmit Singh
Journal:  Curr Pain Headache Rep       Date:  2014-01

Review 8.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

Review 9.  Optimal management of bone metastases in breast cancer patients.

Authors:  Mh Wong; N Pavlakis
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-05-02

Review 10.  Targeting bone physiology for the treatment of metastatic prostate cancer.

Authors:  Karen A Autio; Michael J Morris
Journal:  Clin Adv Hematol Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.